Neuroprotective peptides and peptide-based therapies represent a promising class of disease-modifying approaches for Alzheimer's disease (AD). These short amino acid sequences (typically 5-40 residues) are derived from endogenous neuropeptides or engineered synthetically to protect neurons from amyloid toxicity, oxidative stress, excitotoxicity, and neuroinflammation[1].
Unlike small molecule drugs, peptides can interact with larger surface areas on target proteins, enabling more specific modulation of protein-protein interactions that are difficult to target with traditional pharmaceuticals. The therapeutic rationale for neuroprotective peptides in AD rests on several key observations: peptides can cross the blood-brain barrier with appropriate modifications; they target multiple pathways involved in neurodegeneration simultaneously; and several have demonstrated favorable safety profiles in clinical trials[2].
This category page consolidates companies developing neuroprotective peptide therapeutics for AD, including:
Neurotrope Bioscience (acquired by Acumen Pharmaceuticals) focused on developing bryostatin-based therapeutics for Alzheimer's disease. The company's lead candidate, bryostatin-1 (also known as Altumab or NRO-1), is a protein kinase C (PKC) activator that promotes synaptic plasticity and neurotrophic factor expression.
Cognition Therapeutics is focused on developing small molecule therapeutics targeting sigma-2 receptors to treat Alzheimer's disease and other protein aggregation disorders. The company's lead candidate, CT-1812 (ELND005), is a novel sigma-2 receptor modulator that has progressed through Phase 1 and Phase 2 clinical trials.
Spinogenix is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics targeting synaptic regeneration in Alzheimer's disease and other neurodegenerative conditions.
Prothelia is focused on developing protein replacement therapies and neuroprotective molecules for neurodegenerative diseases.
Alector is developing immune-neurology therapeutics that harness the brain's immune system to treat neurodegenerative diseases. While primarily focused on TREM2 and other immune targets, their approach includes neuroprotective mechanisms.
Neuraly is a clinical-stage biopharmaceutical company exclusively focused on developing GLP-1 receptor agonists for neurodegenerative diseases, including peptide-based approaches.
Brain-derived neurotrophic factor (BDNF) is a critical neurotrophin that supports neuronal survival, synaptic plasticity, and cognitive function. BDNF and its derivatives have been extensively studied for neuroprotective applications:
| Company | Peptide | Target | Stage |
|---|---|---|---|
| Various | BDNF 1-28 | TrkB agonist | Preclinical |
| Various | BDNF loop 1 peptide | TrkB agonist | Preclinical |
| Neurotrope | Bryostatin-1 | PKC activator | Phase 2 |
NAP (NAPVSIPQ) is an 8-amino acid peptide derived from activity-dependent neuroprotective protein (ADNP). It binds to tubulin and promotes microtubule stabilization.
| Company | Product | Stage |
|---|---|---|
| Formerly Allon Therapeutics | Davunetide (AL-108) | Phase 2 |
Peptides designed to prevent or disrupt amyloid-beta aggregation:
| Company | Product | Mechanism | Stage |
|---|---|---|---|
| Various | Aβ aggregation inhibitors | Beta-sheet blockers | Preclinical |
Small molecule/peptide modulators that protect synapses from toxic oligomers:
| Company | Product | Mechanism | Stage |
|---|---|---|---|
| Cognition Therapeutics | CT-1812 | Sigma-2 modulation | Phase 2 |
| Company | Lead Program | Mechanism | Indication | Stage |
|---|---|---|---|---|
| Acumen/NBC | Bryostatin | PKC activation | AD | Phase 2 |
| Cognition Therapeutics | CT-1812 | Sigma-2 | AD | Phase 2 |
| Spinogenix | SPG-302 | Synaptogenesis | AD | Phase 1 |
| Neuraly | NLY01 | GLP-1 | AD/PD | Phase 1-2 |
| Alector | AL001/002 | TREM2 | AD | Phase 2/3 |
The future of peptide-based drugs. Nature Reviews Drug Discovery. 2013. ↩︎
Neuroprotective peptides for neurodegenerative diseases. Drug Discovery Today. 2019. ↩︎